Advert - Daiichi Sankyo – Case AUTH/3649/5/22
-
Date posted18 October 2023
-
SanctionAdvertisement,
-
Case number/s
For failing to make immediately apparent to health professionals in the body of promotional material which referred to the therapeutic use of Nilemdo (bempedoic acid) or Nustendi (bempedoic acid and ezetimibe) in combination with a statin that there was a contraindication regarding concomitant use with simvastatin >40mg daily, and for failing to comply with its undertaking provided in Case AUTH/3504/2/21, Daiichi Sankyo was ruled in breach of the following Clauses of the 2021 Code:
Clause 2 - Bringing discredit upon, and reducing confidence in, the pharmaceutical industry
Clause 3.3 - Failing to comply with an undertaking
Clause 5.1 - Failing to maintain high standards
Clause 6.1 - Misleading impression provided